Germline mutations in highly penetrant autosomal dominant genes explain about 5% of all breast cancer, and heritable mutations in the BRCA1 breast and ovarian cancer susceptibility gene account for 2-3% ofbreast cancer in the general population. Nevertheless, the presence of such mutations is highly predictive of disease development. Since screening for mutations is still technically laborious, we investigated whether the prior probability of being a carrier of a dominant breast cancer susceptibility gene in the youngest affected family member could be used to identify families in which the probability of finding a mutation is sufficiently high. 
ian cancer susceptibility gene account for 2-3% ofbreast cancer in the general population. Nevertheless, the presence of such mutations is highly predictive of disease development. Since screening for mutations is still technically laborious, we investigated whether the prior probability of being a carrier of a dominant breast cancer susceptibility gene in the youngest affected family member could be used to identify families in which the probability of finding a mutation is sufficiently high. Sixty German families with three or more cases ofbreast/ovarian cancer with at least two cases diagnosed under the age of 60 were screened for mutations by SSCP/ CSGE and subsequent direct sequencing. Thirteen germline truncating/splicing mutations in BRCA1 were found in 33% (6/18) of the breast-ovarian cancer families and in 17% (7/42) ofbreast cancer only families. All the families showing mutations in BRCA1 had carrier probabilities of 0.65 or higher. In families with prior carrier probabilities above 0.6, the proportion detected was 0.46 in breastovarian cancer families and 0. 26 fied breast cancer genes of lower penetrance than BRCA1/2. Since screening for mutations is very cost and time intensive, we investigated whether the prior probability of being a carrier of a dominant breast cancer susceptibility gene in the youngest affected family member could be used to identify families in which the probability of finding a mutation is sufficiently high. Here, we report the results from BRCA1 mutation screening of a defined set of families characterised additionally by the probability of segregating breast and ovarian cancer predisposing genes.
Subjects and methods

FAMILIES
Families containing three or more members in the same lineage affected with breast/ovarian cancer with at least two diagnosed under the age of 60 years were ascertained through gynaecologists or in response to press publicity in Germany. Each Germline chain terminating/splicing mutaThe mean age at diagnosis of breast or ovartions in BRCA1 were detected in 13 families ian cancer in all the families with BRCA1 (22%), including six breast-ovarian cancer mutations was 41.9 years, ranging between families and seven families with female breast 33.3 and 47.8 years. This was significantly cancer only. Eleven of the mutations were lower than the mean of 49.5 years in the other unique and included five frameshift deletions, families where no mutations were detected three nonsense mutations, two splice variant (p<0.01). Given the probability of harbouring mutations, and one missense mutation (table a predisposing gene, the mean age at diagnosis 2). The two splice site mutations changed a appears to further characterise families with conserved splice donor site, in one instance, mutations in the BRCA1 gene (fig 1) . and a conserved splice acceptor site in the Discussion other. Thus they are likely to affect the correct We investigated whether it is useful to calculate splicing of the transcript. The missense mutacarrier probabilities for identifying famition is located in the ring finger domain and has lies in which the probability of finding a mutabeen reported in other BRCA1 families. There tion is sufficiently high. For the 60 families fulwas no obvious difference in mutation site filling common criteria specifying the number between those detected in families with and and ages of affected relatives, total of 13 without ovarian cancer. We also found several functionally relevant mutations in BRCA1 new polymorphisms and a new unclassified weredetectedbySSCP/CSGEandsubsequent variant in an intron. The polymorphisms were DNA sequencing. In all the families harbourpresent in both affected and unaffected family ing BRCA1 mutations, the probability of being members, but the unclassified variant in the a carrier of a dominant breast cancer gene in intron was only found in a breast cancer the youngest affected family member was 0.65 patient.
or higher. In families with carrier probabilities 
in breast-ovarian cancer and breast cancer only families. If we take into consideration that SSCP/CSGE is reported to have a sensitivity of about 80%, then the number of families with a mutation may actually be higher.
The prior probabilities for BRCA1 from the Breast Cancer Linkage Consortium study were estimated to be 0.33 for families with four or more cases of breast cancer under 60 years only and 0.73 for breast-ovarian families (without male breast cancer) with four or more cases under the age of 60 years (Easton and Ford, in preparation).'7 Of our 25 families which fall into these categories, BRCA1 mutations were detected in 25% (4/16) of the breast cancer only families and 56% (4/9) of the breastovarian families. Additional prior probabilities for BRCA1 calculated from epidemiological data are 0.30 for families with three cases of breast cancer under 50 years only and 0.17 for two cases of breast cancer under 50 years only (D Easton, personal communication). In our families which fall into these two family types regardless of the total number of affected persons (which is at least three in this study), the proportions with BRCA1 mutations were 14% (1/7) and 16% (2/12), respectively. Even then, of the 60 families studied, we are left with 12 unclassified families, of which one was found to harbour a BRCA1 mutation.
When considering only families for which the probability of carrying a breast cancer susceptibility gene in the youngest affected family member is above 0.6, the proportion of families with detected BRCA1 mutations among breast cancer only families and among families with breast and ovarian cancer are nevertheless both lower than the previously estimated prior probabilities of 30-40% and 70-80%. Since the published prior probabilities were based predominantly on families with four or more cases selected for early onset breast cancer, these estimates cannot be applied to the majority of families now requesting genetic counselling and gene testing.
The advantage of calculating the probability of being a carrier of a dominant breast cancer susceptibility gene is that it provides a common measure for all pedigrees being counselled. For families in which breast/ovarian cancer cases diagnosed under the age of 60 years have occurred in four or more first degree relatives, the probability of segregating breast cancer predisposing genes will be very high, generally above 0.9 regardless of the size of the complete pedigree. In 17 Although in the majority of the families the maximal gene carrier probability of all family members is identical to the gene carrier probability for the youngest affected family member (which we have used in this paper), this is not always the case. In another paper (Chang-Claude et al, in preparation), we will report the influence of the two procedures as well as the effect of using different penetrances on the estimates of gene carrier probability.
The carrier probability can be reduced considerably when the correlation between phenotypes and genotypes is imperfect. For the computation, this situation arises not only with incomplete penetrance of the genotype but also when the obligate carrier is affected with cancer at sites other than the expected phenotypes of cancer of the breast or the ovary. In two of our families with a mutation in BRCA1 showing comparatively low carrier probabilities of 0.65 and 0.68, the obligate carriers were affected with bladder cancer and endometrial cancer, respectively. Increased risks of other cancers in BRCA1 mutation carriers have already been established." We also observed endometrial cancer, cervical cancer, and colon cancer in mutation carriers and obligate carriers in several families with different mutations.
Although not yet formally estimated for BRCA2 mutation carriers, other cancers probably over-represented in BRCA2 mutation carriers include prostate, pancreas, colon, larynx, and ocular melanoma.7 2123 3416 As long as other BRCA1 or BRCA2 associated cancers are not adequately accounted for in the assumed genetic model, the estimated carrier probability will not always be an accurate measure of genetic risk.
It is at present not possible to derive gene specific risks. When the gene frequency and age specific penetrance data for BRCA2, including those for male breast cancer, are available, it will be possible to estimate the probability of carrying a mutation separately for BRCA1 and BRCA2." At present, families with breast and ovarian cancers would be preferably screened initially for mutations in BRCA1 because of the higher prior probability of BRCA1 being involved. 9 The presence of male breast cancers indicates a greater likelihood of the involvement of BRCA2. We also did not detect any BRCA1 mutations in the families with male breast cancer. The risks for a second primary cancer of the breast and the ovary are known to be high among BRCA1 mutation carriers.38
Thus bilateral breast cancer may be more frequently associated with BRCA1. Our results suggest that a particularly young average age at diagnosis may characterise families with BRCA1 mutations. Whether the occurrence of bilateral breast cancer and consistent early age at onset preferably indicate the involvement of BRCA1 or BRCA2 will require formal confirmation.
Using the carrier probability as a measure of genetic risk, it remains difficult to determine the threshold at which families should be included in mutation screening for dominant genes. We detected mutations only in families with a carrier probability above 0.6 in the youngest affected person (say, 35 years), which corresponds to a carrier probability of about 0.3 (or above) for an unaffected female first degree relative of the same age. This translates to a phenotypic risk of about 0.3 up to the age of 79, which corresponds to a relative risk of about 3.0 compared to the general population. At present, we cannot correlate the carrier probabilities with detection of BRCA2. It would be important to screen for BRCA2 mutations in this series of families in order to determine the proportion of the high risk families resulting from BRCA2. The results of the BRCA1 screening suggests that the probability of finding a mutation in families with carrier probabilities of less than 60% may be very low. Certainly a larger series of families will have to be investigated in this fashion to provide better estimates of the probability of detecting mutations in dominant predisposing genes for the different ranges of carrier probabilities.
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